瑞豐高材(300243.SZ):擬投建年產1.6萬噸ACR抗衝加工改性劑項目
格隆匯3月31日丨瑞豐高材(300243.SZ)公佈,公司於2022年3月30日召開第五屆董事會第二次會議、第五屆監事會第二次會議,審議通過了《關於投資建設年產1.6萬噸ACR抗衝加工改性劑項目的議案》。
為了繼續鞏固公司在PVC加工抗衝改性劑的市場地位,滿足市場對ACR產品不斷增長的需求,增強公司市場競爭力,擬投資建設年產1.6萬噸ACR項目,項目投資金額不超過人民幣6000萬元,資金來源為自有資金及自籌資金。項目投產後,公司ACR的產能將由目前的7萬噸增至8.6萬噸,將進一步穩固公司在ACR產品行業市場地位,提升公司盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.